GlassScriptPhysician profile
Gregory M Woolfolk
NPI 1881678324
$19,162.23
in general payments reported to CMS, 2019-2025
51 companies · $4,273 in 2025
The $4,273 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,193 · 2020: $1,406 · 2021: $1,783 · 2022: $2,818 · 2023: $2,981 · 2024: $3,708 · 2025: $4,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $15.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,946.52 |
| Education | $15.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,650.97 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $3,061.95 | 2019-2025 | Linzess, Creon, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,698.55 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,498.35 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $962.48 | 2019-2025 | |
| Pfizer INC. | $746.47 | 2019-2025 | |
| Genzyme Corporation | $639.42 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $591.16 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $427.75 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $402.35 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $386.15 | 2019-2024 | Linzess |
| Lilly USA, LLC | $379.83 | 2024-2025 | Omvoh, Zepbound |
| Novo Nordisk INC | $376.94 | 2019-2025 | Wegovy |
| Edwards Lifesciences Corporation | $346.98 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Intercept Pharmaceuticals, INC. | $344.80 | 2019-2025 | Ocaliva |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Woolfolk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.